- Home
- MKZR vs UBX Comparison
MKZR vs UBX Comparison
Compare MKZR & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- UBX
- Stock Information
- Founded
- MKZR 2012
- UBX 2009
- Country
- MKZR United States
- UBX United States
- Employees
- MKZR N/A
- UBX N/A
- Industry
- MKZR
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- UBX Health Care
- Exchange
- MKZR Nasdaq
- UBX Nasdaq
- Market Cap
- MKZR 31.4M
- UBX 36.9M
- IPO Year
- MKZR N/A
- UBX 2018
- Fundamental
- Price
- MKZR $1.93
- UBX $1.94
- Analyst Decision
- MKZR
- UBX Strong Buy
- Analyst Count
- MKZR 0
- UBX 2
- Target Price
- MKZR N/A
- UBX $7.00
- AVG Volume (30 Days)
- MKZR 197.0K
- UBX 203.3K
- Earning Date
- MKZR 01-01-0001
- UBX 04-14-2025
- Dividend Yield
- MKZR 15.54%
- UBX N/A
- EPS Growth
- MKZR N/A
- UBX N/A
- EPS
- MKZR N/A
- UBX N/A
- Revenue
- MKZR $23,087,751.00
- UBX N/A
- Revenue This Year
- MKZR N/A
- UBX N/A
- Revenue Next Year
- MKZR N/A
- UBX $33.62
- P/E Ratio
- MKZR N/A
- UBX N/A
- Revenue Growth
- MKZR 57.39
- UBX N/A
- 52 Week Low
- MKZR $1.05
- UBX $0.94
- 52 Week High
- MKZR $5.50
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- UBX 48.69
- Support Level
- MKZR N/A
- UBX $1.99
- Resistance Level
- MKZR N/A
- UBX $2.17
- Average True Range (ATR)
- MKZR 0.00
- UBX 0.22
- MACD
- MKZR 0.00
- UBX -0.05
- Stochastic Oscillator
- MKZR 0.00
- UBX 22.41
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.